PTC Therapeutics (PTCT) Short Interest Ratio & Short Volume → Charles Payne’s Gift to Stock Investors (From Unstoppable Prosperity) (Ad) Free PTCT Stock Alerts $32.14 +3.57 (+12.50%) (As of 04/29/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability PTC Therapeutics Short Interest DataCurrent Short Volume10,200,000 sharesPrevious Short Volume10,260,000 sharesChange Vs. Previous Month-0.58%Dollar Volume Sold Short$261.94 millionShort Interest Ratio / Days to Cover11.4Last Record DateApril 15, 2024Outstanding Shares76,700,000 sharesPercentage of Shares Shorted13.30%Today's Trading Volume1,861,643 sharesAverage Trading Volume982,425 sharesToday's Volume Vs. Average189% Short Selling PTC Therapeutics ? Sign up to receive the latest short interest report for PTC Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatPTCT Short Interest Over TimePTCT Days to Cover Over TimePTCT Percentage of Float Shorted Over Time Ad Banyan Hill PublishingNvidia CEO Says It Will Be “the Next Revolution” Beyond AINvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.Click on Adam's shiny forehead for more details. PTC Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/202410,200,000 shares $261.94 million -0.6%N/A11.4 $25.68 3/31/202410,260,000 shares $298.46 million -5.8%N/A10.8 $29.09 3/15/202410,890,000 shares $321.80 million -4.5%N/A10.9 $29.55 2/29/202411,400,000 shares $321.37 million +9.8%N/A10.5 $28.19 2/15/202410,380,000 shares $266.66 million -6.0%N/A9.7 $25.69 1/31/202411,040,000 shares $288.03 million +10.7%N/A10.2 $26.09 Get the Latest News and Ratings for PTCT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/20249,970,000 shares $272.48 million +1.9%N/A7.6 $27.33 12/31/20239,780,000 shares $269.54 million +6.1%N/A7.3 $27.56 12/15/20239,220,000 shares $261.76 million +3.7%N/A6.7 $28.39 11/30/20238,890,000 shares $204.65 million +10.0%N/A5.9 $23.02 11/15/20238,080,000 shares $167.82 million +9.5%N/A5.7 $20.77 10/31/20237,380,000 shares $138.38 million +5.1%N/A5.5 $18.75 10/15/20237,020,000 shares $143.14 million -12.4%N/A6 $20.39 9/30/20238,010,000 shares $179.50 million +8.5%N/A7.9 $22.41 9/15/20237,380,000 shares $193.80 million -0.3%N/A8.5 $26.26 8/31/20237,400,000 shares $292.30 million +2.6%N/A11.9 $39.50 8/15/20237,210,000 shares $297.48 million +2.3%N/A9.2 $41.26 7/31/20237,050,000 shares $284.40 million -5.5%N/A8.6 $40.34 7/15/20237,460,000 shares $292.28 million -3.2%N/A8.6 $39.18 6/30/20237,710,000 shares $313.57 million +2.7%N/A8.9 $40.67 6/15/20237,510,000 shares $326.61 million +18.5%N/A8.5 $43.49 5/31/20236,340,000 shares $266.09 million +16.8%N/A7.3 $41.97 5/15/20235,430,000 shares $300.28 million +4.0%N/A7 $55.30 4/30/20235,220,000 shares $287.83 million -0.4%N/A7.1 $55.14 4/15/20235,240,000 shares $258.17 million -2.4%N/A7.5 $49.27 3/31/20235,370,000 shares $260.12 million -1.5%N/A7.3 $48.44 3/15/20235,450,000 shares $254.73 million +9.0%N/A7.5 $46.74 2/28/20235,000,000 shares $218.35 million +0.4%N/A7.4 $43.67 2/15/20234,980,000 shares $229.78 million -14.1%N/A7.8 $46.14 1/31/20235,800,000 shares $266.16 million +22.6%N/A9.1 $45.89 1/15/20234,730,000 shares $226.00 million -8.7%N/A6.9 $47.78 12/30/20225,180,000 shares $197.72 million +11.4%N/A7.9 $38.17 12/15/20224,650,000 shares $179.03 million +3.3%N/A7.7 $38.50 11/30/20224,500,000 shares $186.71 million -5.1%N/A7.1 $41.49 11/15/20224,740,000 shares $180.36 million -1.5%N/A7.3 $38.05 10/31/20224,810,000 shares $181.91 million +1.9%6.9%7.5 $37.82 10/15/20224,720,000 shares $243.74 million -6.2%6.8%7.6 $51.64 9/30/20225,030,000 shares $252.51 million -7.7%7.2%8.8 $50.20 9/15/20225,450,000 shares $292.39 million +8.1%7.8%8.7 $53.65 8/31/20225,040,000 shares $251.70 million -1.8%7.3%6.7 $49.94Nvidia CEO Says It Will Be “the Next Revolution” Beyond AI (Ad)Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.Click on Adam's shiny forehead for more details. PTCT Short Interest - Frequently Asked Questions What is PTC Therapeutics' current short interest? Short interest is the volume of PTC Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 15th, traders have sold 10,200,000 shares of PTCT short. Learn More on PTC Therapeutics' current short interest. What is a good short interest ratio for PTC Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. PTCT shares currently have a short interest ratio of 11.0. Learn More on PTC Therapeutics's short interest ratio. Which institutional investors are shorting PTC Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of PTC Therapeutics: Wolverine Asset Management LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is PTC Therapeutics' short interest increasing or decreasing? PTC Therapeutics saw a drop in short interest in the month of April. As of April 15th, there was short interest totaling 10,200,000 shares, a drop of 0.6% from the previous total of 10,260,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does PTC Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to PTC Therapeutics: Maravai LifeSciences Holdings, Inc. (5.93%), Galapagos NV (2.30%), NewAmsterdam Pharma (0.85%), Geron Co. (9.04%), Keros Therapeutics, Inc. (6.27%), Amphastar Pharmaceuticals, Inc. (11.01%), Avidity Biosciences, Inc. (13.37%), Schrödinger, Inc. (8.88%), Agios Pharmaceuticals, Inc. (12.15%), Syndax Pharmaceuticals, Inc. (11.30%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short PTC Therapeutics stock? Short selling PTCT is an investing strategy that aims to generate trading profit from PTC Therapeutics as its price is falling. PTCT shares are trading up $3.35 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against PTC Therapeutics? A short squeeze for PTC Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of PTCT, which in turn drives the price of the stock up even further. How often is PTC Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PTCT, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: MRVI Short Squeeze GLPG Short Squeeze NAMS Short Squeeze GERN Short Squeeze KROS Short Squeeze AMPH Short Squeeze RNA Short Squeeze SDGR Short Squeeze AGIO Short Squeeze SNDX Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:PTCT) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsNvidia CEO Says It Will Be “the Next Revolution” Beyond AIBanyan Hill PublishingCharles Payne’s Gift to Stock InvestorsUnstoppable ProsperityDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithElon Musk Secret Crypto Plot ExposedCrypto 101 MediaThe AI stock to buy right nowStockEarnings